Stockscreener 앱 받기
24.00
1.48%
0.35
시간 외 거래:
24.00
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Q4 2025 earnings preview - MSN
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? - Yahoo Finance
Kingdon Capital Management L.L.C. Purchases 400,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Granahan Investment Management LLC Has $6.10 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Algert Global LLC Cuts Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Assessing Whether Syndax Pharmaceuticals (SNDX) Still Looks Undervalued After Its Recent Strong Run - simplywall.st
Syndax Pharmaceuticals, Inc. $SNDX Position Reduced by Prosight Management LP - MarketBeat
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Its 81.5% One Year Share Price Gain - simplywall.st
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
SNDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Syndax Pharmaceuticals at Barclays Conference: Strategic Growth Focus - Investing.com
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avoiding Lag: Real-Time Signals in (SNDX) Movement - Stock Traders Daily
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - The Globe and Mail
Syndax Pharmaceuticals stock hits 52-week high at $22.91 By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00 - MarketBeat
SNDX: JP Morgan Raises Price Target to $45Maintains Overweigh - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year HighStill a Buy? - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Wall Street Zen Upgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to Hold - MarketBeat
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating - MSN
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push - TipRanks
Can Syndax Pharmaceuticals Inc. stock maintain growth trajectory2026 Momentum Check & AI Forecasted Stock Moves - Naître et grandir
Syndax Pharmaceuticals, Inc. $SNDX is Knott David M Jr's 7th Largest Position - MarketBeat
Vanguard Group Inc. Buys 104,683 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Market Wrap: Is Syndax Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Bitget
Syndax Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Syndax Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-03-03 - Seeking Alpha
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Pipeline Progress Or Stretching Recent Share Gains - simplywall.st
SNDX Receives Buy Rating as Citigroup Raises Price Target to $57 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup - MarketBeat
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Bitget
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript - Insider Monkey
Syndax Pharmaceuticals Q4 Revenue Ramp To US$68.7 Million Tests Bullish Growth Narrative - simplywall.st
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Q4 Revenue Beat And Wider Loss - simplywall.st
Syndax (SNDX) Q4 2025 Earnings Call Transcript - Intellectia AI
Syndax Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Syndax Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Discipline and Rules-Based Execution in SNDX Response - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals (SNDX) Reports Strong 2025 Earnings and Growth Prospects - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results - MarketBeat
Syndax Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax (SNDX) Projects Stable Operating Expenses and Path to Pro - GuruFocus
1.20%
0.06%
자본화:
|
볼륨(24시간):